Drugs /

ko-947

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon intravenous administration, KO-947 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.

Clinical Trials

View Clinical Trials for ko-947

Ko-947 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating ko-947, 1 is phase 1 (0 open).

BRAF Mutation, HRAS Mutation, and KRAS Mutation are the most frequent biomarker inclusion criteria for ko-947 clinical trials.

Head and neck squamous cell carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in ko-947 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ko-947
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ko-947 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Categories [2]:
ERK inhibitor
Drug Target(s) [2]:
MAPK1, MAPK3

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.